RxSight, Inc.(RXST)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• RxSight faces a critical inflection point as revenue growth has reversed from a 77.6% peak in 2023Q4 to a 18.5% contraction in 2026Q1, signaling potential saturation or structural headwinds in its specialized ophthalmic market.
• While the company maintains a robust 76.1% gross margin, the inability to achieve operating leverage—evidenced by a -57.7% operating margin—suggests that the current SG&A-heavy commercial model may be unsustainable.
• Investors should monitor the tightening liquidity buffer, as cash reserves have declined to $17.6 million, necessitating a more disciplined approach to capital allocation to avoid further equity dilution.